Fig. 5
From: A novel model for predicting immunotherapy response and prognosis in NSCLC patients
The differences in the number of RDW-SD, MCV, PDW, CD3+CD8+, APTT, P-LCR, Ca, MPV, CD4+/CD8+ and AST between the high-risk and low-risk groups
Fig. 5 | Cancer Cell International